Welling Mick M, Mongera Sandra, Lupetti Antonella, Balter Henia S, Bonetto Valeria, Mazzi Ulderico, Pauwels Ernest K J, Nibbering Peter H
Department of Radiology, Division of Nuclear Medicine, Leiden University Medical Center (LUMC), Leiden, The Netherlands.
Nucl Med Biol. 2002 May;29(4):413-22. doi: 10.1016/s0969-8051(02)00292-5.
A technetium-99m-labeled peptide derived from ubiquicidine, further referred to as 99mTc-UBI 29-41, targets bacterial and fungal infections, but not sterile inflammatory processes, in experimental animals. This paper reports on the radiochemical and biological features of this radioactive agent and the importance of the amino acid sequence of UBI 29-41 for imaging of infections. Radiochemical analyses of 99mTc-UBI 29-41 and a radiolabeled scrambled version of this peptide, i.e. 99mTc-Sc-UBI 29-41, revealed that both peptides were labeled rapidly (within 10 min) and effectively with little colloid formation (less than 5% of the total radioactivity) and very little free pertechnetate (or radioactive intermediates) in the preparations containing radiolabeled peptide. Furthermore, association of the peptides with bacteria could be competed with excess unlabeled peptide and this association proved to be temperature-dependent. Based on this in vitro data we concluded that labeling of peptides with 99mTc by this direct method is rapid, efficient, and safe. Scintigraphy demonstrated that radioactivity is rapidly removed from the circulation (half-lifes of UBI 29-41 and Sc-UBI 29-41 were 16 and 21 min, respectively) mainly by renal clearance. Analysis of murine blood revealed that only a small proportion of the intravenously injected 99mTc-peptides is associated with blood cells. Although both radiolabeled peptides accumulated rapidly at sites of infection, the values for 99mTc-UBI 29-41 were higher (P < 0.05) than for 99mTc-Sc-UBI 29-41. Moreover, injection of excess unlabeled UBI 29-41, but not Sc-UBI 29-41, into Staphylococcus aureus-infected mice prior to injection of 99mTc-UBI 29-41 significantly (P < 0.05) reduced the accumulation of this radiopharmaceutical at the site of infection. In addition, we observed significantly (P < 0.01) higher amounts of 99mTc-UBI 29-41 at the site of infection in mice using a carrier-free radiolabeled UBI 29-41 as compared with unpurified preparations containing radiolabeled UBI 29-41. This in vivo data indicates that the amino acid sequence of 99mTc-UBI 29-41 contributes to its accumulation at the site of infection.
一种源自泛素化肽的锝-99m标记肽,以下简称99mTc-UBI 29-41,在实验动物中可靶向细菌和真菌感染,但对无菌性炎症过程无靶向作用。本文报道了这种放射性制剂的放射化学和生物学特性,以及UBI 29-41氨基酸序列对感染成像的重要性。对99mTc-UBI 29-41及其放射性标记的乱序肽(即99mTc-Sc-UBI 29-41)进行放射化学分析,结果显示两种肽均能快速(10分钟内)且有效地标记,胶体形成少(占总放射性不到5%),且含放射性标记肽的制剂中游离高锝酸盐(或放射性中间体)极少。此外,肽与细菌的结合可被过量未标记肽竞争,且这种结合被证明是温度依赖性的。基于这些体外数据,我们得出结论,用这种直接方法用99mTc标记肽快速、高效且安全。闪烁扫描显示放射性主要通过肾脏清除快速从循环中清除(UBI 29-41和Sc-UBI 29-41的半衰期分别为16分钟和21分钟)。对小鼠血液的分析表明,静脉注射的99mTc-肽只有一小部分与血细胞结合。尽管两种放射性标记肽都能在感染部位迅速蓄积,但99mTc-UBI 29-41的值高于99mTc-Sc-UBI 29-41(P<0.05)。此外,在注射99mTc-UBI 29-41之前,向金黄色葡萄球菌感染的小鼠体内注射过量未标记的UBI 29-41而非Sc-UBI 29-41,可显著(P<0.05)降低这种放射性药物在感染部位的蓄积。此外,我们观察到,与含放射性标记UBI 29-41的未纯化制剂相比,使用无载体放射性标记UBI 29-41的小鼠感染部位99mTc-UBI 29-41的量显著更高(P<0.01)。体内数据表明,99mTc-UBI 29-41的氨基酸序列有助于其在感染部位的蓄积。